Primer: Antengene (6996 HK) - Aug 2026
Antengene is a commercial-stage biotech transitioning towards profitability, driven by its lead asset XPOVIO® and strategic out-licensing of...
91 Views
China Healthcare Weekly Wrap (27-31 July)
Hutchmed 1H26 results takeaways; CSPC and Antengene released positive profit alert; Kelun's sac-TMT gained NMPA review for 1L TNBC; AZ's CLDN18.2...
115 Views
APAC Healthcare Weekly (June 28) – Insilico, Abbisko, Nippon Shinyaku, Otsuka, Yuhan Corp, Medytox
Few Chinese companies signed outlicensing deals. Nippon Shinyaku’s partner Regenxbio will resubmit gene therapy drug candidate to FDA. Otsuka...
144 Views
China Healthcare Weekly Wrap (22-26 June)
This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...
128 Views
APAC Healthcare Weekly (June 14) – Wuxi AppTec, Remegen, CSPC Pharma, Takeda, SK Bioscience Alteogen
US DoD designated Wuxi AppTec as a “Chinese military company.” Takeda’s zasocitinib tops BMS’ Sotyktu in head-to-head trial. Alteogen secured...
132 Views